183 related articles for article (PubMed ID: 21888181)
1. The efficacy and safety of amoxicillin-clavulanic acid 1000/125mg twice daily extended release (XR) tablet for the treatment of bacterial community-acquired pneumonia in adults.
Prabhudesai PP; Jain S; Keshvani A; Kulkarni KP
J Indian Med Assoc; 2011 Feb; 109(2):124-7. PubMed ID: 21888181
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae.
Siquier B; Sánchez-Alvarez J; García-Mendez E; Sabriá M; Santos J; Pallarés R; Twynholm M; Dal-Ré R;
J Antimicrob Chemother; 2006 Mar; 57(3):536-45. PubMed ID: 16446376
[TBL] [Abstract][Full Text] [Related]
3. Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults.
File TM; Lode H; Kurz H; Kozak R; Xie H; Berkowitz E;
Antimicrob Agents Chemother; 2004 Sep; 48(9):3323-31. PubMed ID: 15328092
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains.
File TM; Garau J; Jacobs MR; Wynne B; Twynholm M; Berkowitz E
Int J Antimicrob Agents; 2005 Feb; 25(2):110-9. PubMed ID: 15664480
[TBL] [Abstract][Full Text] [Related]
5. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent.
White AR; Kaye C; Poupard J; Pypstra R; Woodnutt G; Wynne B
J Antimicrob Chemother; 2004 Jan; 53 Suppl 1():i3-20. PubMed ID: 14726431
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy and tolerability of pristinamycin vs amoxicillin-clavulanic acid combination in the treatment of acute community-acquired pneumonia in hospitalized adults].
Poirier R; Chardon H; Beraud A; Debieuvre D; Petitprez P; Montestruc F; Lilienthal F; Janus C
Rev Pneumol Clin; 1997; 53(6):325-31. PubMed ID: 9616826
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of pharmacokinetically enhanced amoxicillin-clavulanate at 2,000/125 milligrams twice daily for 5 days versus amoxicillin-clavulanate at 875/125 milligrams twice daily for 7 days in the treatment of acute exacerbations of chronic bronchitis.
Sethi S; Breton J; Wynne B
Antimicrob Agents Chemother; 2005 Jan; 49(1):153-60. PubMed ID: 15616290
[TBL] [Abstract][Full Text] [Related]
8. The development of pharmacokinetically enhanced amoxicillin/clavulanate for the management of respiratory tract infections in adults.
File TM
Int J Antimicrob Agents; 2007 Dec; 30 Suppl 2():S131-4. PubMed ID: 18029151
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of azithromycin 1 g once daily for 3 days in the treatment of community-acquired pneumonia: an open-label randomised comparison with amoxicillin-clavulanate 875/125 mg twice daily for 7 days.
Paris R; Confalonieri M; Dal Negro R; Ligia GP; Mos L; Todisco T; Rastelli V; Perna G; Cepparulo M
J Chemother; 2008 Feb; 20(1):77-86. PubMed ID: 18343748
[TBL] [Abstract][Full Text] [Related]
10. Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults.
Garau J; Twynholm M; Garcia-Mendez E; Siquier B; Rivero A;
J Antimicrob Chemother; 2003 Nov; 52(5):826-36. PubMed ID: 14563899
[TBL] [Abstract][Full Text] [Related]
11. Evolution of amoxicillin/clavulanate in the treatment of adults with acute bacterial rhinosinusitis and community-acquired pneumonia in response to antimicrobial-resistance patterns.
File TM; Benninger MS; Jacobs MR
Clin Lab Med; 2004 Jun; 24(2):531-51. PubMed ID: 15177852
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of oral pharmacokinetically enhanced amoxycillin-clavulanate 2000/125 mg, twice daily, versus oral amoxycillin-clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adults.
Petitpretz P; Chidiac C; Soriano F; Garau J; Stevenson K; Rouffiac E;
Int J Antimicrob Agents; 2002 Aug; 20(2):119-29. PubMed ID: 12297361
[TBL] [Abstract][Full Text] [Related]
13. Amoxicillin/clavulanate potassium extended release tablets: a new antimicrobial for the treatment of acute bacterial sinusitis and community-acquired pneumonia.
Benninger MS
Expert Opin Pharmacother; 2003 Oct; 4(10):1839-46. PubMed ID: 14521493
[TBL] [Abstract][Full Text] [Related]
14. Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia.
Bradley JS; Arguedas A; Blumer JL; Sáez-Llorens X; Melkote R; Noel GJ
Pediatr Infect Dis J; 2007 Oct; 26(10):868-78. PubMed ID: 17901791
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of twice-daily amoxycillin/clavulanate in lower respiratory tract infections.
Balgos AA; Rodriguez-Gomez G; Nasnas R; Mahasur AA; Margono BP; Tinoco-Favila JC; Sansores-Martinez RH; Hassan M; Beppo O; Wongsa A; Cukier A; Vargas F
Int J Clin Pract; 1999; 53(5):325-30. PubMed ID: 10695094
[TBL] [Abstract][Full Text] [Related]
16. Once-daily oral gatifloxacin vs three-times-daily co-amoxiclav in the treatment of patients with community-acquired pneumonia.
Lode H; Magyar P; Muir JF; Loos U; Kleutgens K;
Clin Microbiol Infect; 2004 Jun; 10(6):512-20. PubMed ID: 15191378
[TBL] [Abstract][Full Text] [Related]
17. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.
File TM; Mandell LA; Tillotson G; Kostov K; Georgiev O
J Antimicrob Chemother; 2007 Jul; 60(1):112-20. PubMed ID: 17537866
[TBL] [Abstract][Full Text] [Related]
18. Extended release amoxicillin/clavulanate: optimizing a product for respiratory infections based on pharmacodynamic principles.
Jacobs MR
Expert Rev Anti Infect Ther; 2005 Jun; 3(3):353-60. PubMed ID: 15954852
[TBL] [Abstract][Full Text] [Related]
19. An open-label, randomized comparison of levofloxacin and amoxicillin/clavulanate plus clarithromycin for the treatment of hospitalized patients with community-acquired pneumonia.
Lin TY; Lin SM; Chen HC; Wang CJ; Wang YM; Chang ML; Wang CH; Liu CY; Lin HC; Yu CT; Hsieh LL; Kuo HP; Huang CD
Chang Gung Med J; 2007; 30(4):321-32. PubMed ID: 17939262
[TBL] [Abstract][Full Text] [Related]
20. Development of a twice daily dosing regimen of amoxicillin/clavulanate.
Bax R
Int J Antimicrob Agents; 2007 Dec; 30 Suppl 2():S118-21. PubMed ID: 17983732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
